The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

defined as onset of persistent 50% or greater reduction in eGFR according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation compared with baseline, onset of persistent ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's OZEMPIC Approval Heat Up the Chronic Kidney disease Therapeutic market | DelveInsight The FDA's recent approval of OZEMPIC ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

Now, there's a new benefit to taking Ozempic: It may help manage chronic kidney disease (CKD). On January 28, the U.S. Food and Drug Administration (FDA) approved the GLP-1 drug to reduce the risk ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new research shows. Compared to another ...

EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease ... loss and renal protection. With Ozempic now FDA-approved for use in diabetic kidney disease (DKD) patients, adoption ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new research shows. Compared to another common ...